Stifel analyst James Condulis tells investors that the move lower in Fulcrum Therapeutics (FULC) this morning “surprises us” and looks “overdone.” While the firm believes some thought total mean HbF may comfortably be greater than 20% given the strength of the initial cut at ASH, the firm thinks “overly nitpicking 19.3% is splitting hairs and misses the bigger picture” as these data surpassed the physician “bar” and that pociredir is reaching HbF levels expected to be highly protective of disease. Even wit ...

Group 1 - Shares in Agios Pharmaceuticals experienced a significant decline of 50% following mixed results from its Phase 3 trial of the sickle cell disease drug, mitapavit [1] - The Phase 3 trial had two primary endpoints, achieving success in one while failing to meet the other [2] - The trial demonstrated a statistically significant response in average hemoglobin levels, with 40.6% of treated patients showing improvement compared to 2.9% in the placebo group [3] Group 2 - Despite the failure to significantly reduce sickle cell pain crises (SCPCs), management highlighted the potential value of mitapavit due to its "anti-hemolytic profile" [5][7] - The company plans to engage with the FDA and submit a marketing application for mitapavit in the first quarter of 2026 [5][7] - The market reaction to the trial results suggests a potential overreaction, indicating that there may still be investment opportunities in Agios Pharmaceuticals [5]

Core Insights - Agios Pharmaceuticals announced topline results from the RISE UP Phase 3 trial of mitapivat, an oral pyruvate kinase activator, for patients with sickle cell disease, demonstrating significant improvements in hemoglobin response and hemolysis markers [1][5][6] Trial Results - The trial met its primary endpoint of hemoglobin response, with 40.6% of patients in the mitapivat arm achieving a significant increase in hemoglobin levels compared to 2.9% in the placebo group [12] - Mitapivat showed a statistically significant improvement in average hemoglobin concentration and indirect bilirubin levels, but the reduction in annualized rate of sickle cell pain crises did not achieve statistical significance [2][3][12] - The safety profile of mitapivat was consistent with previous trials, with a similar proportion of adverse events reported in both mitapivat and placebo groups [19] Patient Outcomes - Patients who achieved hemoglobin response experienced clinically meaningful benefits in the annualized rate of sickle cell pain crises and hospitalizations, as well as improvements in fatigue scores [4][12][13] - The average change in PROMIS Fatigue score was -5.19 for hemoglobin responders, indicating a clinically meaningful improvement [13] Regulatory and Future Plans - Agios plans to engage with the FDA to discuss the findings and intends to submit a marketing application for mitapivat for sickle cell disease in early 2026 [15][16] - The company is also focused on the potential U.S. approval of PYRUKYND for thalassemia, anticipated in December 2025, and will take steps to reduce operating expenses [16] About Sickle Cell Disease - Sickle cell disease is a rare inherited blood disorder characterized by abnormal hemoglobin production, leading to severe complications and increased healthcare needs [18]

Core Insights - Fulcrum Therapeutics reported positive results from the 12 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease (SCD) [2][3] Efficacy Data - The mean absolute fetal hemoglobin (HbF) increased by 8.6% from a baseline of 7.6% to 16.2% after 12 weeks of treatment, with 7 out of 16 patients achieving HbF levels greater than 20% [4][10] - The proportion of F-cells increased from 34% at baseline to 67% at 12 weeks, indicating pan-cellular induction of HbF [4][10] - Key markers of hemolysis showed meaningful improvements, including a mean increase in total hemoglobin of 0.9 g/dL, from 7.8 g/dL to 8.7 g/dL [10] - A trend of reduced vaso-occlusive crisis (VOC) rates was observed, with 50% of patients reporting no VOCs during the treatment period [10] Safety Profile - Pociredir was generally well-tolerated, with no treatment-related serious adverse events (SAEs) reported, and all treatment-related adverse events (AEs) were Grade 1 [3][10] - The safety profile observed in the 12 mg dose cohort was consistent with previously reported data [10] Company Overview - Fulcrum Therapeutics is focused on developing small molecules for genetically defined rare diseases, with pociredir as its lead clinical program aimed at increasing HbF expression for SCD treatment [8][9]

Core Viewpoint - AB Science has received a Notice of Allowance for a US patent covering the use of masitinib in treating sickle cell disease, providing protection until November 2040, which enhances its intellectual property portfolio [1][3]. Company Overview - AB Science is a pharmaceutical company founded in 2001, specializing in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [12][13]. Product Development - Masitinib is being developed as a treatment for severe forms of sickle cell disease, which accounts for approximately 65% of cases. The drug targets mast cells, which play a critical role in the disease's complications [3][4]. - The clinical development of masitinib in sickle cell disease is part of the SICKMAST collaborative program, which is funded with €9.2 million and aims to demonstrate efficacy in a phase 2 clinical trial [5]. Medical Need - Sickle cell disease is a significant public health challenge, with around 300,000 children born with the condition annually, potentially rising to 400,000 by 2050. The disease leads to early death and high social burden [6][10]. - Current treatment options do not fully prevent life-threatening complications, highlighting a significant medical need for effective therapies [10]. Scientific Insights - Masitinib has shown survival benefits in preclinical models, with treated mice experiencing no vaso-occlusive crises (VOC) or deaths, indicating its potential effectiveness [4]. - The drug acts as an inhibitor of key kinases involved in mast cell activation, which is crucial for addressing the inflammatory aspects of sickle cell disease [8][9].